Can venetoclax/venetoclax completely cure leukemia?

Venetoclax is a targeted drug mainly used to treat chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and other types of leukemia. This drug promotes cancer cell apoptosis by inhibiting the function of BCL-2 protein, so it has significant anti-tumor effects. Although venetoclax has shown good efficacy in treating leukemia, especially in some relapsed or drug-resistant patients, whether it can "completely cure" leukemia is still a complex issue.

First of all, leukemia is a highly heterogeneous cancer, that is, it has diverse cell types and mutation mechanisms. Although venetoclax can effectively kill tumor cells and prolong patient survival, it cannot ensure long-term remission for all types of leukemia patients, especially when the disease burden is heavy or multi-drug resistance mechanisms exist. Therefore, although venetoclax can induce significant remissions in some patients, it is not the "ultimate treatment" for leukemia. For types such as acute myeloid leukemia (AML), the patient's condition often requires combination with other treatments, such as chemotherapy or immunotherapy, to improve the effectiveness of the treatment.

Secondly, complete cure of leukemia usually relies on comprehensive treatment strategies, including targeted therapy, chemotherapy, stem cell transplantation and other comprehensive methods. Venetoclax functions as an adjunct in these treatment strategies rather than as a single treatment option. It can significantly slow disease progression in certain cases, but in most cases, cure remains a challenge.

Therefore, although venetoclax has shown good efficacy in the treatment of leukemia, whether it can completely cure leukemia still requires longer clinical observation and further research.

Reference materials:https://www.venclexta.com/